Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of QLS5132 injection in combination therapy for advanced solid tumors
CTR20261286Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of QLS5132 in Nonhematologic neoplasms, sponsored by Qilu Pharmaceutical. Started May 2026; status: active.
02
Drugs
QLS5132
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20261286.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261286.